Ascendis Pharma A/S
ASND
$159.26
-$2.27-1.40%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -42.69% | 191.58% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -42.69% | 191.58% | |||
| Cost of Revenue | 23.32% | 21.39% | |||
| Gross Profit | -48.48% | 232.46% | |||
| SG&A Expenses | 24.36% | 11.38% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 16.72% | 8.85% | |||
| Operating Income | -26,959.42% | 100.38% | |||
| Income Before Tax | -147.08% | 63.08% | |||
| Income Tax Expenses | -3.47% | 3.14% | |||
| Earnings from Continuing Operations | -142.84% | 62.40% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -142.84% | 62.40% | |||
| EBIT | -26,959.42% | 100.38% | |||
| EBITDA | -6,185.88% | 101.70% | |||
| EPS Basic | -141.89% | 63.81% | |||
| Normalized Basic EPS | -146.11% | 64.47% | |||
| EPS Diluted | -141.89% | 63.81% | |||
| Normalized Diluted EPS | -146.11% | 64.47% | |||
| Average Basic Shares Outstanding | 0.39% | 3.91% | |||
| Average Diluted Shares Outstanding | 0.39% | 3.91% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||